Abstract: The invention provides a method capable of readily discriminating pathologic conditions and judging selection of a therapeutic drug, the degree of the therapeutic effect, discontinuation of medication, etc., wherein stages quantitatively judged by digitizing substances contained in urine, which is different from conventional methods for judging stages of an interstitial pneumonitis which are performed by observation of mucous lesions with endoscopy requiring the skill or by analysis of histological samples collected from the living body. The method measures the value of main metabolites of prostaglandin E (PGE-MUM) concentration in urine and judges stages between the pre-remission phase of interstitial pneumonitis.

Abstract: The invention provides a method capable of readily discriminating pathologic conditions and judging selection of a therapeutic drug, the degree of the therapeutic effect, discontinuation of medication, etc., wherein stages quantitatively judged by digitizing substances contained in urine, which is different from conventional methods for judging stages of an ulcerative colitis and an interstitial pneumonitis which are performed by observation of mucous lesions with endoscopy requiring the skill or by analysis of histological samples collected from the living body. The method measures the value of main metabolites of prostaglandin E (PGE-MUM) concentration in urine and judges stages between the pre-remission phase of and the remission phase of ulcerative colitis. The method also measures the value of the PGE-MUM concentration in urine and judges stages between the active phase and the non-active phase of interstitial pneumonitis.

Abstract: The invention provides a method capable of readily discriminating pathologic conditions and judging selection of a therapeutic drug, the degree of the therapeutic effect, discontinuation of medication, etc., wherein stages quantitatively judged by digitizing substances contained in urine, which is different from conventional methods for judging stages of an ulcerative colitis and an interstitial pneumonitis which are performed by observation of mucous lesions with endoscopy requiring the skill or by analysis of histological samples collected from the living body. The method measures the value of main metabolites of prostaglandin E (PGE-MUM) concentration in urine and judges stages between the pre-remission phase of and the remission phase of ulcerative colitis. The method also measures the value of the PGE-MUM concentration in urine and judges stages between the active phase and the non-active phase of interstitial pneumonitis.

Abstract: The invention provides a method capable of readily discriminating pathologic conditions and judging selection of a therapeutic drug, the degree of the therapeutic effect, discontinuation of medication, etc., wherein stages quantitatively judged by digitizing substances contained in urine, which is different from conventional methods for judging stages of an ulcerative colitis and an interstitial pneumonitis which are performed by observation of mucous lesions with endoscopy requiring the skill or by analysis of histological samples collected from the living body. The method measures the value of main metabolites of prostaglandin E (PGE-MUM) concentration in urine and judges stages between the pre-remission phase of and the remission phase of ulcerative colitis. The method also measures the value of the PGE-MUM concentration in urine and judges stages between the active phase and the non-active phase of interstitial pneumonitis.

Abstract: A hypercholesterolemia therapeutic agent containing lycopene as an effective ingredient. The hypercholesterolemia therapeutic agent comprises a soft-capsulated drug, and the soft-capsulated drug comprises a soft capsule which comprises gelatin and glycerin, and contents which comprise lycopene, .beta.-carotene, .alpha.-carotene, d-.alpha. tocopherol and a mixture of a wheat germ oil and a vegetable oil, which contents are packed into the soft capsule.

Abstract: A hypercholesterolemia therapeutic agent containing lycopene as an effective ingredient. The hypercholesterolemia therapeutic agent comprises a soft-capsulated drug, and the soft-capsulated drug comprises a soft capsule which comprises gelatin and glycerin, and contents which comprise lycopene, .beta.-carotene, .alpha.-carotene, d-.alpha. tocopherol and a mixture of a wheat germ oil and a vegetable oil, which contents are packed into the soft capsule.